Reinhart Partners’s Theravance Biopharma TBPH Stock Holding History

Reinhart Partners’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-164,249	Closed	-$1.8M	–	122
2015 Q3	$1.8M	Sell	164,249 -1,940	-1%	-$24.7K	0.18%	70
2015 Q2	$2.16M	Buy	166,189 +99,579	+149%	+$1.54M	0.2%	69
2015 Q1	$1.16M	Sell	66,610 -5,240	-7%	-$96.1K	0.08%	132
2014 Q4	$1.07M	Buy	+71,850	New	+$1.25M	0.08%	133

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Reinhart Partners's TBPH Position: Q4 2015 in Review

Reinhart Partners sold out of Theravance Biopharma (TBPH) in Q4 2015, closing a stake of 164,249 shares — an estimated $1.8M sold.

Reinhart Partners first reported a position in TBPH in Q4 2014 and held it in 4 quarters. The position peaked at $2.16M in Q2 2015. 83 funds tracked by Wall St. Rank hold TBPH as of Q4 2015.

Reinhart Partners reported no remaining Theravance Biopharma position as of Q4 2015 after selling out during the quarter.
Reinhart Partners sold 164,249 Theravance Biopharma shares in Q4 2015, an estimated $1.8M.
Reinhart Partners first reported a position in Theravance Biopharma in Q4 2014 and held it in 4 quarters.
Reinhart Partners's Theravance Biopharma position peaked at $2.16M in Q2 2015.
83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2015.

Based on Reinhart Partners's 13F filing for Q4 2015, filed 3 Feb 2016.